drugset / Trial / NCT02027662

Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules

NCT02027662 ↗

Phase 2/3 Completed 61 enrolled Fresenius Medical Care Deutschland GmbH
RandomizedFactorialOpen-labelTreatment

Summary

Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced. This study is about efficacy and safety of the new drug formulation and compares it to the "old" formulation which are film-coated tablets.

Timeline

Start
2014-01
Primary completion
2015-04
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Osvaren Granules Unknown — —
Comparator Osvaren film-coated tablets Unknown — —